-
'Where is she?' The desperate search for Venezuela's missing
-
Former Barca teen star Fati seals permanent Monaco switch
-
No business as usual after shock World Cup exit, say German FA
-
German rail regulator backs Italian firm in competition spat
-
Pope appeals to Catholic traditionalists to avoid schism
-
Ancelotti shows Brazil his worth at World Cup but concerns remain
-
US Supreme Court upholds transgender sports bans
-
Stocks rise, yen at 40-year low against dollar
-
US Supreme Court rejects Trump bid to restrict birthright citizenship
-
Australia hold West Indies to 125-7 in World Cup semi-final
-
Serena set for remarkable Wimbledon return, Swiatek survives scare
-
Defending champ Swiatek survives scare to reach Wimbledon second round
-
Africa EV firm Spiro accused of torturing Uganda employees
-
US Supreme Court upholds state bans on transgender athletes in school
-
PSG's Portugal forward Ramos signs five-year AC Milan deal
-
Tourists soldier on in Rome despite heatwave
-
Inflation slows in top eurozone economies as ECB ponders next move
-
Record number of 'new millionaires' in 2025, says UBS
-
Starmer boosts budget to modernise UK military before exit
-
UN calls for food, shelter to help Venezuela quake survivors
-
Stocks mostly higher, yen stays near 40-year low against dollar
-
Merz faces mockery over praise of Germany's World Cup team
-
Data centres emitting more CO2 than thought: study
-
Ride-share group BlaBlaCar taps AI for 20-country expansion
-
Over 1 million migrants apply for Spain's mass regularisation
-
Escaping heat, forgetting war: Kyiv locals hit the beach
-
Germany questions footballing identity after fresh World Cup failure
-
Thousands march to demand illegal migrants leave South Africa
-
MEXC Lists Ondo's Tokenized Strategy Preferred Stock on Spot Market
-
Serena set for remarkable Wimbledon return
-
Stocks climb, yen stays near 40-year low against dollar
-
Outgoing UK PM Starmer announces 'record' defence spending
-
Swim star Marchand limps out of French nationals as Europeans loom
-
Paralluelo joins Barca women's departures
-
UN says transport infrastructure must adapt to climate
-
Police hunt for Monaco bomb suspect after Ukrainian-born businessman wounded
-
Sommer, Acerbi, Darmian, De Vrij leave Inter Milan
-
Sommer, Acerbi, Darmian leave Inter Milan
-
Germany's labour market dilemma: rising unemployment despite vacancies
-
'Waiting like torture': Turks despair as Schengen visa delays mount
-
Skating allows Russian, Belarussians to return as neutrals
-
Venezuela rescuers in final push to find survivors as families mourn
-
Russian double Olympic figure skating champion Dmitriev dies aged 58
-
Over 1 million migrants apply for Spain's mass regularisation: PM
-
S. Africa deploys police as anti-migrant protests loom
-
Thousands from Philippine sect protest pro-Duterte senator's graft case
-
Monaco parcel bomb blast wounds Ukrainian oligarch
-
South Africa repatriations top 25,000 ahead of anti-immigrant ultimatum
-
Sweden face France's attacking firepower at the World Cup
-
Taiwan raids tech firms in China AI chip smuggling probe
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
K.Thomson--BTB